Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS006 plus CHOP in previously untreated DLBCL
NCT03485118Phase 2Completed
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- May 2016
- Primary completion
- Aug 2016
- Modality
- IgG Antibodies
01
Overview
A Phase 2 trial of zuberitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd.. Started May 2016; status: completed.
02
Drugs
zuberitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03485118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03485118.